Rebecca Araujo

DocwireNews

Two studies have directly linked mechanisms of aging to melanoma spread and treatment resistance.The findings by teams at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Bloomberg School of Public Health were published in <a href="https://cancerdiscovery.aacrjournals.org/content/10/9/1282">Cancer Discovery</a> and in <a href="https://clincancerres.aacrjournals.org/content/26/21/5709?sf131133586=1">Clinical Cancer Research</a>, respectively.In the first study, investigators combined fibroblasts, skin tissue generating cells, from people age 25 to 35 or 55 to 65 with lab-created artificial skin and melanoma cells. When exposed to anti-cancer drugs, cells combined with aged fibroblasts resisted cell death, but the researchers reported that this rarely occurred in cells cultured with young fibroblasts. The cells cultured with aged fibroblasts also consistently upregulated FATP2, a fatty acid transporter, and increased uptake of fatty acids from the environment in and around the tumor.The team then assessed the impact of inhibiting the BRAF oncogene pathway, which is linked to cancer cell development, while simultaneously depleting FATP2 in mice. They found that BRAF-targeted therapy alone worked to temporarily reduce tumor volume in older mice, but FATP2 inhibition eliminated the tumors for the full 60 days the mice were monitored.&ldquo;Taking up a lot of fat protects melanoma cells during therapy,&rdquo; explained first author Ashani Weeraratna, PhD, in a <a href="https://www.eurekalert.org/pub_releases/2020-11/jhm-aia103120.php">press release</a>.In the second study, Dr. Weeraratna&rsquo;s team retroactively evaluated responses of 1,343 patients with melanoma who were treated with the anti-angiogenesis drug Avastin. Angiogenesis occurs when the blood supply to tumors transports cancer cells to other parts of the body to enable metastasis.Patients age 45 or older showed virtually no benefit from Avastin, while patients under age 45 had longer progression-free survival, despite angiogenesis increasing with age. Upon further investigation, the team uncovered that older patients showed decreased expression of the angiogenesis-promoting gene VEGF, which Avastin is designed to block. Instead, another protein, sFRP2, was causing angiogenesis in patients over age 55.&ldquo;<a href="https://www.docwirenews.com/cardiology/cac-helps-id-cvd-risk-in-women-receiving-rt-for-breast-cancer/">Cancer</a> treatment is not one-size-fits-all,&rdquo; said Dr. Weeraratna. &ldquo;Our research shows that younger patients can have very different responses to treatment than older patients. Recognizing that the age of a patient can affect response to treatment is critical to providing the best care for all patients.&rdquo;<blockquote class="twitter-tweet">
Age may cause identical cancer cells with the same mutations to behave differently. In animal and laboratory models of melanoma cells, age was a primary factor in treatment response. <a href="https://t.co/f84YtmEhGS">https://t.co/f84YtmEhGS</a>
&mdash; Hopkins Med News (@HopkinsMedNews) <a href="https://twitter.com/HopkinsMedNews/status/1323275283844116480?ref_src=twsrc%5Etfw">November 2, 2020</a>
</blockquote>

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Latest News

Studies Find Connection Between Age and Melanoma Treatment Resistance

Skin Cancer

Two studies have directly linked mechanisms of aging to melanoma spread and treatment resistance.
 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe